Our results suggested that TNFSF13 expression was upregulated in GBM and associated with immunosuppression, which supported the claim that TNFSF13 could be a potential diagnostic marker and treatment target in the clinical management of glioma patients. The gene discussed is TNFSF13; the disease is central nervous system cancer.